补充β-氨酸可改善由单克罗他林诱导的肺高血压引起的右心室重塑
Hongling Su1,2, Bo Li2, Zhaoxia Guo2
1The First Clinical Medical College of Lanzhou University Lanzhou P. R. China.
Pulmonary circulation
|January 26, 2026
概括
补充β-氨酸 (β-Ala) 改善了右心室 (RV) 功能,并在患有肺高血压 (PH) 的老鼠中减少了重塑. 这表明β-Ala可能是与PH相关的心脏功能障碍的潜在治疗方法.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺高血压 (PH) 导致肺血管阻力增加和右心力衰竭.
- 右心室 (RV) 改造和功能障碍是PH的关键并发症.
研究的目的:
- 为了研究β-氨酸 (β-Ala) 对RV重塑和功能障碍在单氨酸 (MCT) 诱导的PH大鼠模型的影响.
- 探索β-Ala在PH的潜在治疗效果背后的分子机制.
主要方法:
- 鼠被诱导PH使用单色素 (MCT) 和治疗β-Ala.
- 评估RV功能是使用RV静缩压 (RVSP) 和RV缩指数 (RVHI).
- 分子信号通路 (MAPK,AKT),亡标记物和基因表达被分析通过西方斑点和qPCR;RV组织学评估过度缩小和纤维化.
主要成果:
- 在MCT诱导的PH大鼠中,β-Ala显著改善了RVSP和RVHI.
- β-Ala调节的MAPK/AKT信号传递,减少了亲亡的标记物 (Bax,Caspase-3分裂) 和增加了抗亡的标记物 (Bcl-2).
- 组织学分析显示β-Ala减弱的RV缩和纤维化.
结论:
- 在肺高血压的老鼠模型中,β-氨酸减轻了RV重塑和功能障碍.
- β-Ala的治疗作用似乎涉及MAPK/AKT通路和亡的调节.
- β-Ala显示出作为PH相关的右心脏功能障碍的潜在治疗剂的希望.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
621
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
621
Nucleosome Remodeling
11.1K
Nucleosomes are the basic units of chromatin compaction. Each nucleosome consists of the DNA bound tightly around a histone core, which makes the DNA inaccessible to DNA binding proteins such as DNA polymerase and RNA polymerase. Hence, the fundamental problem is to ensure access to DNA when appropriate, despite the compact and protective chromatin structure.
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
11.1K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
594
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
594
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
464
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
493
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
493
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
611
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
611


